• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Carl Feldbaum joins Trovagene's board of directors

Carl Feldbaum joins Trovagene's board of directors

January 8, 2015
CenterWatch Staff

Trovagene, a developer of cell-free molecular diagnostics, has announced that Carl Feldbaum, president emeritus of the Biotechnology Industry Organization (BIO), a biotechnology trade association, has been appointed to its board of directors. He also will be chairman of the company's Corporate Governance and Nominating committee.

"I am certain that his guidance and contributions to our board will be of great benefit to our company, as we integrate our technology into treatment protocols to improve the standard of care for cancer patients," said Antonius Schuh, Ph.D., CEO of Trovagene.

Feldbaum said, "From both professional and family experiences, I am aware that various cancers are known to be driven by certain DNA mutations. With advances in the development of targeted therapies that treat cancer more effectively, Trovagene's cancer monitoring system provides information about specific tumor mutations and their changes over time, which can help physicians treat patients optimally.”

As president of BIO from 1993 until 2005, Feldbaum led the organization to represent more than 1,000 biotechnology companies, academic institutions and state biotechnology centers internationally. He currently is a member of the board of directors of Actelion Pharmaceuticals, and is chairman of its Nominating and Governance committee. Since 2006, he has worked on the board of directors of Exelixis. Feldbaum previously was a member of the board of directors of Connetics from 2005 until its acquisition by Stiefel Laboratories in 2006. He also works as director of BIO Ventures for Global Health and The Life Sciences Foundation, both nonprofit organizations.

Earlier in his career, Feldbaum was chief of staff to Sen. Arlen Specter of Pennsylvania, and founded Palomar, a national security "think tank" in Washington, D.C. Before founding Palomar, Feldbaum was assistant to the secretary of energy, served as the inspector general for defense intelligence in the Department of Defense and was a member of the Watergate Special Prosecution Force.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing